• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

ACADIA Pharmaceuticals

edit

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson’s disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer’s disease psychosis, for which it is initiating a Phase II feasibility study.

Recent Milestones

edit

• 
  ACADIA Pharmaceuticals — ACADIA Pharmaceuticals Announces $86 Million Equity Financing (12/13/12)
  Posted 12/13/12 at 4:47am via yahoo.com
• 
  ACADIA Pharmaceuticals received $15M in Venture Round funding. (1/11/11)
  Posted 1/11/11 at 8:19pm via dowjones.com
• 
  Went public with stock symbol NASDAQ:ACAD.
  Posted 1/11/11 at 8:20pm
• 
  ACADIA Pharmaceuticals added Uli Hacksell as President and CEO.
  Posted 1/11/11 at 8:19pm
• 
  ACADIA Pharmaceuticals added Thomas H. Aasen as Executive Vice President, CFO.
  Posted 1/11/11 at 8:19pm

Videos

Screenshots

edit

Stock Price

Sources

1. Public Acadia Pharma To Raise $15M From NEA, Venrock, Others (fis.dowjones.com) [edit]
ACADIA Pharmaceuticals Announces $86 Million Equity Financing (finance.yahoo.com) [edit]